Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Dyadic International, Inc. - Common Stock
(NQ:
DYAI
)
0.4211
-0.0230 (-5.18%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 12, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Dyadic International, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Dyadic to Present at Industry Events in November
October 30, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
October 25, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic Appoints Doug Pace to Its Executive Leadership Team
October 09, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic International Earnings Perspective: Return On Capital Employed
↗
March 30, 2023
Via
Benzinga
Earnings Outlook For Dyadic International
↗
March 28, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
↗
October 06, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
October 05, 2023
Via
Benzinga
Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic
October 05, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic to Present at Industry and Investor Events in October
September 29, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells
September 26, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using Dapibus™
September 19, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic to Present at BioProcess International
September 12, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic Announces Continued Progress Towards Commercialization of Animal-Free Recombinant Serum Albumin
August 07, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023
July 26, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate
July 24, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic Announced an MoU with Bangladesh’s State-Owned Pharmaceutical Company to Facilitate Biopharmaceutical Research and Biomanufacturing Capacity
June 21, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic to Participate at Upcoming Events in June
June 01, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic to Participate at Two Industry Events in May
May 10, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic Announces Collaboration to Commercialize Animal-Free Alternative Proteins Using Dapibus™
May 08, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
April 26, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic Receives U.S. Patent for Manufacturing Seasonal and Pandemic Influenza Vaccines from its Proprietary C1 Protein Production Platform
April 18, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic Announces Expanded Licensing Agreement to Develop and Commercialize Vaccines and Biologics for African Continent
April 12, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic to Present at World Vaccine Congress Washington 2023
March 30, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic to Report 2022 Year End Financial Results on Wednesday, March 29, 2023
March 15, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic Provides Phase 1 Clinical Trial Update for its DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
March 07, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic to Present at Roth Investor Conference and Upcoming Industry Events
March 01, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
↗
February 10, 2023
Via
Benzinga
Dyadic to Participate in Two Upcoming Investor Conferences
February 02, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
January 24, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
Dyadic Announces Sale of Equity Interest in Alphazyme
January 19, 2023
From
Dyadic International, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
